Jan 8, 2009 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. FDA has approved AllerNaze (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older.
The details can be read here.
No comments:
Post a Comment